![]() |
市場調查報告書
商品編碼
1284224
到 2028 年的電生理學市場預測——按產品、適應症(房室結折返性心動過速、心房顫動、其他適應症)、最終用戶和地區進行的全球分析Electrophysiology Market Forecasts to 2028 - Global Analysis By Product, Indication (Atrioventricular Nodal Reentry Tachycardia, Atrial fibrillation and Other Indications), End User and By Geography |
根據 Stratistics MRC 的數據,2022 年全球電生理學市場規模將達到 75.7 億美元,預計到 2028 年將達到 144.7 億美元,預測期內復合年增長率為 11。預計增長速度為.4%。
電生理學 (EP) 是研究體內電活動的科學領域。 也稱為侵入性心臟電生理學,它是一系列分析心臟電活動的測試。 它通過測量心臟的電系統和活動來診斷和治療心律失常和心律失常。 該測試使用導管和線電極來評估通向心臟的血管的電活動。
根據 2022 年世界肥胖地圖集,到 2030 年,美洲三分之一的男性 (34.41%) 和近五分之二的女性 (39.72%) 的 BMI 預計將達到 30 公斤/平方米。
由於冷凍消融、激光消融、超聲消融和增強映射技術等創新技術的引入,預計全球電生理學市場在預測期內將會增長。 由於吸煙和過量飲酒等生活方式的選擇,千禧一代心力衰竭 (HF) 和心臟驟停病例的增加也推動了市場的發展。 此外,EP 監測系統的小型化增加了全球電生理行業對這些設備的需求,尤其是在 COVID-19 期間。 因此,心律和殘疾部門密切關注植入式電生理 (EP) 設備的遠程監控和編程能力。
建立 EP 實驗室的成本多年來顯著上升,原因包括醫療保健提供者的整合、複雜醫療程序的使用導致成本增加、政府法規不斷變化以及資源限制等。 儘管各國對心律失常的認識和電生理產品在心律失常治療中的作用不斷增加,但這限制了這些產品的廣泛使用。
由於患者數量增加、心臟測繪系統普及、心血管疾病意識增強、可支配收入增加、醫療保健基礎設施改善以及與發達國家相比相對寬鬆的指導方針,新興市場正在蓬勃發展。預計將為這個市場的玩家。 在過去十年中,由於患者人數增加、心血管疾病相關死亡人數增加以及醫療旅遊增加,新興市場的外科手術數量穩步增加。
對翻新產品不斷增長的需求對市場進入者,尤其是小型生產商構成了重大挑戰。 為了提高市場地位並為電生理產品建立重要的用戶群,市場參與者可能會降低價格或採用更好或更先進的技術來滿足未滿足的市場需求。
COVID-19 的意外爆發對全球醫療器械業務產生了各種影響。 由於全球醫院就診人數下降,某些類別總體上受到了負面影響。 另一方面,感染 COVID-19 的既往心髒病患者更有可能發生心髒病發作或充血性心力衰竭。 這種減少限制了對電生理設備的需求並阻礙了市場增長。 此外,在市場上運營的主要市場參與者在 2020 年上半年見證了這些設備產生的收入下降。
EP 實驗室儀器部門的推動因素包括用於開發新型電生理記錄系統的公共和私人資金增加、射頻消融手術數量的增加、射頻消融手術與其他消融技術相比的成本效益、有利的增長是預計,部分原因是這些產品的可用性增加 EP 實驗室設備進一步細分為 EP X 射線系統、3D 映射系統、EP 記錄系統、EP 遠程控制系統等。
房顫 (AF) 部分預計將在預測期內實現最高的複合年增長率。 心房顫動 (AF),通常稱為 AFib,是最常見的心律失常之一,會導致不規則、快速的心律。 在心房顫動中,心臟的上腔室迅速收縮,阻礙了血液從心房到心室的正常泵送,導致血栓形成。 房顫患者更容易出現嚴重的心臟問題,例如中風和心力衰竭。 據說心房顫動會導致大約六分之一的人中風。
由於不健康的生活方式以及吸煙和飲酒的增加導致心力衰竭、心臟驟停和心律失常的患病率上升,預計北美在預測期內將佔據最大的市場份額。. 此外,該地區存在適當的報銷政策也是推動市場擴張的主要因素之一。 在美國,大多數人肥胖且易患心血管疾病,這可能會促進市場增長。
由於主要市場參與者在該地區國家/地區的活動增加,預計亞太地區在預測期內的複合年增長率最高。 在印度和中國等新興國家,由於醫療保健基礎設施的快速發展和可支配收入的增加,預計對電生理設備的需求將增加。 此外,醫療基礎設施的快速發展和不斷上升的醫療支出預計將推動該地區行業領先公司的投資。
2022 年 1 月,雅培獲得了美國食品和藥物管理局 (FDA) 對採用 EnSite 全極技術 (OT) 的 EnSite X EP 系統的許可。 它是一個新的心臟繪圖平台,可在美國和歐洲使用,旨在幫助醫生更好地治療異常心律。 該系統創建了一個非常詳細的心臟三維圖,幫助醫生識別出現異常節律的心臟區域,然後進行治療。
2021 年 10 月,Boston Scientific, Inc. 達成最終協議,以 17.5 億美元收購 Bayliss Medical Company, Inc.。 此次收購將有助於波士頓科學公司。
2020 年 12 月,Acutus 宣佈在歐洲推出帶有 CE 標誌的 AcQBlate 力傳感消融系統。 AcQBlate 力傳感消融系統採用市售的金頭灌注力敏感射頻消融導管設計,用於電生理標測和射頻消融。
According to Stratistics MRC, the Global Electrophysiology Market is accounted for $7.57 billion in 2022 and is expected to reach $14.47 billion by 2028 growing at a CAGR of 11.4% during the forecast period. Electrophysiology (EP) is a scientific discipline that investigates electrical activity in the body. It is also known as invasive cardiac electrophysiology, and it is a series of tests that analyse the electrical activity of the heart. It is used to diagnose and treat cardiac rhythm disorders or arrhythmias by measuring the electrical system or activity of the heart. During the test, catheters and wire electrodes are utilised to assess electrical activity in blood vessels that lead to the heart.
According to the World Obesity Atlas 2022, 1 in 3 men (34.41%) and nearly two-fifths of women (39.72%) are expected to have a BMI of 30kg/m2 by 2030 in the Americas area.
The introduction of innovative technologies such as cryoablation, laser ablation, ultrasonic ablation, and enhanced mapping technologies is expected to increase the global electrophysiology market over the forecast period. The market is also being fueled by the increased prevalence of heart failure (HF) and cardiac arrest cases among millennials as a result of lifestyle choices such as smoking and excessive alcohol consumption. Furthermore, smaller EP monitoring systems have raised demand for these devices in the worldwide electrophysiology industry, particularly during the COVID-19 period. As a result, the cardiac rhythm and failure divisions are paying careful attention to remote monitoring and the programming capabilities of implanted electrophysiology (EP) devices.
The cost of constructing the EP laboratory has risen significantly over the years due to variables such as healthcare provider consolidation, growing expenses due to the usage of complicated medical treatments, changing government restrictions, and limited resources. This is limiting the penetration of these goods, despite the fact that knowledge of arrhythmia and the usefulness of electrophysiological products to treat arrhythmia is increasing in various nations.
Emerging markets are expected to offer significant growth opportunities for players in this market, owing to their increasing patient population, rising adoption of cardiac mapping systems, growing awareness of CVDs, rising disposable incomes, improving healthcare infrastructure, and comparatively lenient guidelines when compared to developed countries. During the last decade, emerging countries have seen a steady increase in the number of surgical procedures, driven by a larger target patient population, an increase in CVD-related fatalities, and increased medical tourism.
The rising demand for refurbished products presents a significant challenge for market participants, particularly small producers. To enhance their market position and build a significant user base for their electrophysiological goods, market players must either drop their pricing or develop better or more advanced technologies that can answer the market's unmet needs.
The unexpected breakout of the COVID-19 pandemic has had a mixed influence on the worldwide medical equipment business. Some categories suffered an overall negative impact as a result of the global drop in the number of patient visits to hospitals. Patients with pre-existing cardiac disease who are exposed to COVID-19, on the other hand, are more likely to experience a heart attack or develop congestive heart failure. The decline has led to limited demand for electrophysiology devices, hampering the growth of the market. Additionally, key market players operating in the market witnessed decline in the revenues generated from these devices in the first half of 2020.
The EP laboratory devices segment is estimated to have a lucrative growth, Due to the increasing public-private funding for the development of novel electrophysiology recording systems, the rising number of RF ablation procedures, the cost-effectiveness of RF ablation procedures in comparison to other ablation techniques, and the expanding availability of these products in major markets. EP laboratory devices are further subdivided into EP X-Ray systems, 3D mapping systems, EP recording systems, EP remote steering systems, and others.
The atrial fibrillation (AF) segment is anticipated to witness the highest CAGR growth during the forecast period. Atrial fibrillation (AF), commonly known as AFib, is one of the most prevalent kinds of arrhythmia, resulting in irregular and fast heart rhythms. It happens when rapid electric signals drive the upper chamber of the heart to contract quickly, preventing the atria from pumping blood into the ventricles regularly, resulting in blood clots. Atrial fibrillation patients are more likely to get serious heart issues such as strokes and heart failure. AFib contributes to nearly one in every six strokes.
North America is projected to hold the largest market share during the forecast period because of the rising prevalence of heart failure (HF), cardiac arrest, and cardiac arrhythmia as a result of unhealthy lifestyles and increased smoking and alcohol intake. The presence of proper reimbursement policies in the region is also one of the primary factors likely to drive market expansion. While the majority of the population in America is obese, they are predisposed to cardiovascular disease, which is likely to boost market growth.
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to increasing activities by key market players in countries in the region. The fast growth of healthcare infrastructure and rising disposable income in developing countries such as India and China are expected to drive up demand for electrophysiology devices. Furthermore, it is projected that top industry companies in the region will boost their investment due to the region's fast rising healthcare infrastructure and growing healthcare spending.
Some of the key players profiled in the Electrophysiology Market include Japan LifeLine Co., Ltd., MicroPort Scientific Corporation, Osypka Medical, Abbott, GE Healthcare, Siemens Healthcare GmbH, APN Health, LLC, Koninklijke Philips N.V., Medtronic, Stereotaxis, Inc., Johnson & Johnson, Japan LifeLine Co., Ltd., Boston Scientific Corporation and Acutus Medical, Inc.
In January 2022, Abbott has received the U.S. Food and Drug Administration for its EnSite X EP System with EnSite Omnipolar Technology (OT). It is a new cardiac mapping platform available in the US and across Europe that is designed to help physicians better treat abnormal heart rhythms. The system creates highly detailed three-dimensional maps of the heart to help physicians identify and then treat areas of the heart where abnormal rhythms originate.
In October 2021, Boston Scientific Corporation has entered into a definitive agreement to acquire Baylis Medical Company Inc. for $1.75 billion. The acquisition will help Boston Scientific.
In December 2020, Acutus has announced the launch of their AcQBlate Force Sensing Ablation System in Europe after getting the CE Mark. The AcQBlate Force Sensing Ablation System, designed with commercially available gold-tipped, irrigated, force-sensing radiofrequency ablation catheter, it is used for electrophysiology mapping and RF ablation.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.